Literature DB >> 6780618

Duration of the immune response in subjects inoculated with antimeningococcal A and C vaccines kept in storage at -20 degrees C and at 4 degrees C: influence of pre-vaccination titres on the vaccinal response.

S Grinstein, T M Kahn, S Tisminetsky, M Donadio, G Weyland.   

Abstract

The antibody titres in 250 subjects, aged 5 to 22 years, who were vaccinated with a mannitol-lyophilized antimeningococcal A + C vaccine, stable only when stored at -20 degrees C, were followed for two years. As measured by indirect haemagglutination (IHA) and indirect immunofluorescence (IF) techniques, titres for both A and C Neisseria meningitidis antibodies remained high. Two years after vaccination titres of antibodies against type A showed fourfold increase over the initial titres in from 46% to 100% of groups of subjects and against type C in from 42% to 80%. For 130 subjects vaccinated with a new lactose-lyophilized antimeningcoccal A + C vaccine (presumed stable at 4 degrees C) antibody titres were measured up to 16 months after inoculation with this vaccine stored at -20 degrees C and also after storage for several periods at 4 degrees C. Antibody titres in all these subjects had fallen to their initial titres by 16 months. The importance of evaluating the results on subjects showing low initial titres (less than or equal to 1/8 as measured by IHA) is discussed, as inclusion of high initial titres influences the extent of the response.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6780618      PMCID: PMC2134062          DOI: 10.1017/s0022172400068819

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  14 in total

1.  Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3.

Authors:  J B Robbins; L Myerowitz; J K Whisnant; M Argaman; R Schneerson; Z T Handzel; E C Gotschlich
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

2.  Serologic studies of meningococcal infection and polysaccharide vaccination.

Authors:  M S Artenstein; B L Brandt; E C Tramont; W C Branche; H D Fleet; R L Cohen
Journal:  J Infect Dis       Date:  1971-09       Impact factor: 5.226

3.  Meningococcal infections. 5. Duration of polysaccharide-vaccine-induced antibody.

Authors:  M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

4.  Effect of group-A meningococcal vaccine in army recruits in Finland.

Authors:  P H Mäkelä; H Käyhty; P Weckström; A Sivonen; O V Renkonen
Journal:  Lancet       Date:  1975-11-08       Impact factor: 79.321

5.  Meningococcal infections. 4. Stability of group A and group C polysaccharide vaccines.

Authors:  M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

6.  Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Authors:  R Gold; M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

7.  Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A.

Authors:  R L Myerowitz; R E Gordon; J B Robbins
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

8.  Antibody responses to meningococcal polysaccharide vaccines.

Authors:  B L Brandt; M S Artenstein; C D Smith
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

9.  A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.

Authors:  M H Wahdan; F Rizk; A M el-Akkad; A A el-Ghoroury; R Hablas; N I Girgis; A Amer; W Boctar; J E Sippel; E C Gotschlich; R Triau; W R Sanborn; B Cvjetanović
Journal:  Bull World Health Organ       Date:  1973-06       Impact factor: 9.408

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.